News
Dupilumab – The First Biologic Umbrellaing Type 2 Inflammation Treatment: How Does It Work and Who Is It For?
A new drug is entering the market for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps – the biologic product Dupixent®. The active ingredient is dupilumab, a fully human monoclonal antibody administered subcutaneously using a pre-filled syringe.
Interaction of the 'Big Five' Helps Predict Depression
Experts refer to the 'Big Five' as a personality model that encompasses the following five…
Effect of 3 Different Doses of Trazodone on QT Interval Length
Patients diagnosed with depression often also suffer from cardiovascular diseases, including heart…
What Did the Patent for the Synthesis of Highly Purified Trazodone Bring?
Trazodone is a modern antidepressant that is used in the treatment of various types of depression,…
Long-term Clinical and Radiological Results of Implantation of Cementless Corail Stem
The Corail femoral stem with extensive hydroxyapatite coating for cementless implantation was…
Immunotherapy of Cancer Diseases
Immunotherapeutic strategies have been successfully utilized recently in the treatment of various malignancies....
Dynamics of Allergy Development in Children
The prevalence of allergic diseases in children in developed countries has been steadily increasing…
Use of Bilastine in Pediatrics − Pathway to Improving Concentration and Performance of Young Allergy Sufferers
In the treatment of allergic diseases, especially in children, safety, good tolerability, simple…
Reflection of Progress in Hemophilia Treatment in Current WFH Recommendations
In June 2020, the new, third guidelines of the World Federation of Hemophilia (WFH) were…
Emicizumab Changes the Lifestyle of Patients with Hemophilia A
At the World Federation of Hemophilia (WFH) meeting, data were presented regarding the impact of…